Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Inimmune Corporation
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06302426CT.gov Trial of INI-4001 in Patients With Advanced Solid Tumours | — | Recruiting | — | — | — |
NCT04705818CT.gov Combining Epigenetic And Immune Therapy to Beat Cancer. | — | Completed | — | — | — |
NCT04900818CT.gov Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04521686CT.gov Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | — | Active Not Recruiting | — | — | — |
NCT04392505CT.gov Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study | — | Active Not Recruiting | — | — | — |
NCT04261075CT.gov IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. | — | Completed | — | — | — |
NCT03889275CT.gov A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors | — | Completed | — | — | — |
NCT03946800CT.gov A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03665129CT.gov IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03238027CT.gov A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors | — | Completed | — | — | — |
Show 15 more trialsShow fewer
NCT03094286CT.gov Durvalumab in HIV-1 Patients With Solid Tumors | — | Completed | — | — | — |
NCT03089645CT.gov MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel. | — | Completed | — | — | — |
NCT02938793CT.gov Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors | — | Terminated | — | — | — |
NCT02900157CT.gov Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02805660CT.gov Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC | — | Terminated | — | — | — |
NCT02777710CT.gov Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers | — | Completed | — | — | — |
NCT02671435CT.gov A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02556463CT.gov A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors | — | Terminated | — | — | — |
NCT02537418CT.gov Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens | — | Active Not Recruiting | — | — | — |
NCT02301130CT.gov Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors | — | Completed | — | — | — |
NCT02261220CT.gov A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02205333CT.gov A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies | — | Terminated | — | — | — |
NCT02141347CT.gov Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma | — | Completed | — | — | — |
NCT01938612CT.gov A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours | — | Completed | — | — | — |
NCT01693562CT.gov A Phase 1/2 Study to Evaluate MEDI4736 | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | Inimmune Corporation | P2 | B · 58 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Durvalumab in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →